Naro, Chiara
Antonioni, Ambra
Medici, Vanessa
Caggiano, Cinzia
Jolly, Ariane
de la Grange, Pierre
Bielli, Pamela
Paronetto, Maria Paola
Sette, Claudio http://orcid.org/0000-0003-2864-8266
Funding for this research was provided by:
Fondazione AIRC per la ricerca sul cancro ETS (IG23416, MFAG21899, IG27896)
Ministero della Salute (Ricerca Corrente 2022, RF-2016-02363460)
Article History
Received: 1 December 2023
Accepted: 15 February 2024
First Online: 27 February 2024
Declarations
:
: Our study highlights the cis-acting regulatory features underlying susceptibility to transcriptional and post-transcriptional variations induced by splicing-targeting drugs; it reveals IR as the prominent pattern induced by both direct (Ind/PlaB) and indirect (THZ531) inhibition of splicing and uncovers the 3’-end mRNA processing as a druggable vulnerability for advanced PC.